Medacta Reports 9.7% Revenue Growth Amid Softening US Market
Medacta Group SA reported above-market revenue growth of 9.7% in constant currency for its first semester 2026 results, with a solid margin in the high twenties despite an unexpected softening in the US market.
The company's CEO, Francesco Siccardi, commented on the performance: 'In the first half of 2026, we delivered another robust performance with a sustained above-market growth and a solid margin.'
Medita recorded Group revenue of Euro 368 million, a rise of 9.7% in constant currency and 7.0% in Euros against an exceptionally strong comparable base.
The growth was delivered across all business lines and geographies, due to continued differentiating innovations, the successful attraction of new surgeons, and sustained focus on medical education.